Seven analysts target USD 233.43 for DaVita stock

Published on 10/15/2026 at 21:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 3.55 billion in the second quarter. DaVita stock costs EUR 167.78 on October 15, 2026 at 9:51 p.m. CEST.

Analyst view and trading date

MarketBeat reported a USD 233.43 average target from seven analysts on October 13, 2026.
DaVita revenue reached USD 3.55 billion in the second quarter, up 5.2 percent year over year.
DaVita stock costs EUR 167.78 at Lang & Schwarz on October 15, 2026 at 9:51 p.m. CEST.
DaVita is scheduled to report its next results on October 23, 2026.

Isometrische 3D-Darstellung von Dialyseklinik, Labor, Heimversorgung und integrierter Patientenpflege — Isometrische 3D-Illustration der vollständigen Wertschöpfungskette in der Nierenversorgung von DaVita Inc. US23918K1088, Illustration mit AI erstellt.

Seven analysts put DaVita's average 12-month target at USD 233.43 on October 13, 2026, according to MarketBeat. The same report listed four buy ratings and three hold ratings. The NYSE quote was USD 188.93 at 3:58 p.m. ET on October 15, 2026, up 4.55 percent from the previous close. DaVita stock was at EUR 167.78 at Lang & Schwarz on October 15, 2026 at 9:51 p.m. CEST.

Second-quarter revenue reached USD 3.55 billion

DaVita's second-quarter revenue was USD 3.55 billion, an increase of 5.2 percent from the year-earlier quarter, while earnings per share came to USD 4.02 versus USD 3.88 consensus. MarketBeat reported the figures on October 13, 2026. The revenue comparison gives the analyst target a recent operating backdrop, while reimbursement and coverage changes remain relevant risks for the dialysis provider.

Stock remains below its yearly high

The USD 188.93 NYSE quote stood 23.66 percent below DaVita's 52-week high of USD 247.49 and 87.06 percent above its low of USD 101.00 on October 15, 2026. Trading volume was 429,777 shares against an average of 753,910, leaving the session below its three-month activity level.

Valuation and October results date

DaVita's market capitalization was USD 12.1 billion and its price-to-earnings ratio was 16.59 on October 15, 2026. The company is scheduled to release its next earnings report on October 23, 2026, according to Investing.com.

Comparison with peers

DaVita Inc. (NYSE, USD): plus 4.55 percent, P/E 16.59, market capitalization USD 12.1 billion
Fresenius Medical Care (NYSE, USD): plus 2.62 percent, P/E 11.89, market capitalization USD 11.8 billion
HCA Healthcare (NYSE, USD): minus 0.33 percent, P/E 15.68, market capitalization USD 101.5 billion

Price, valuation and the next date

DaVita combines a USD 233.43 analyst average target with a USD 12.1 billion market capitalization and a scheduled October 23, 2026 earnings date. The price comparison remains split between the euro quote for German investors and the USD listing on the NYSE.

DaVita was trading at EUR 167.78 at Lang & Schwarz on October 15, 2026 at 9:51 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of DaVita stock.